Bupropion hydrochloride ER is a Small Molecule owned by GSK, and is involved in 45 clinical trials, which were completed.

Bupropion is a selective inhibitor of the neuronal re-uptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin) and does not inhibit either monoamine oxidase. The blockade of norepinephrine and serotonin reuptake at the neuronal membrane is weaker for bupropion than for tricyclic antidepressants. The increase in norepinephrine may attenuate nicotine withdrawal symptoms and the increase in dopamine at neuronal sites may reduce nicotine cravings and the urge to smoke.

The revenue for Bupropion hydrochloride ER is expected to reach a total of $663m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bupropion hydrochloride ER NPV Report.

Bupropion hydrochloride ER is currently owned by GSK. Bausch Health Companies is the other company associated in development or marketing of Bupropion hydrochloride ER.

Bupropion hydrochloride ER Overview

Bupropion hydrochloride (Zyban/ Elontril/ Wellbutrin/ Wellbutrin XL, Zyntabac/ Wellbutrin XR/ Wellbutrin LR) is an antidepressant of the aminoketone class. It is formulated as extended release tablets, and film-coated extended release tablets for oral route of administration. Bupropion hydrochloride is indicated for the treatment of major depressive disorder, major depressive illness with seasonal affective disorder, and depression and it is also indicated for the treatment of nicotine dependence in adults aged 18 and older as an aid to smoking cessation.

The drug candidate was under development for the treatment of major depressive disorder in China. It was also under development for the treatment of Attention deficit hyperactivity disorder.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Bupropion hydrochloride ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Bupropion hydrochloride ER
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
  • Sponsor Company: GSK
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.